ESMO Guides for Patients: Disclaimer and declaration of interest

Disclaimer

ESMO Guides for Patients are prepared in collaboration with the Anticancer Fund as a service to patients, to help patients and their relatives better understand the nature of their cancer type and understand the best treatment choices available. Please note that information in these Guides for Patients does not replace a medical consultation. ESMO recommends that patients ask their doctors about what tests or types of treatments are needed for their type and stage of disease.

Patient information based on the ESMO Clinical Practice Guidelines - Conflict of interest disclosures

  • Antonio Aglione: No conflicts of interest to declare
  • William Allum: No conflicts of interest to declare
  • Dirk Arnold: Research grants – Roche, Sanofi
  • Michele Baccarani: Honoraria from Novartis, Bristol-Myers Squibb, Pfizer and Ariad for participation to advisory boards and as a speaker at scientific and educational meetings.
  • Jane Beveridge: No conflicts of interest to declare
  • Jean-Yves Blay: No conflicts of interest to declare
  • Greet Boland: No conflicts of interest to declare
  • Gauthier Bouche: No conflicts of interest to declare
  • Guy Bouguet: No disclosure at time of going online
  • Joaquim Bellmunt: Consultant or Advisory Role - Lilly, Pierre Fabre and Sanofi Aventis
  • An Billiau: Medical writer of Celsus Medical Writing LLC. – Honoraria from Anticancer Fund
  • Paolo Casali: Consultancy/Honoraria: Amgen Domplé, ARIAD, Bayer, GlaxoSmithKline, Infinity, Janssen Cilag, Merck Sharp & Dohme, Novartis, Pfizer, PharmaMar, Sanofi
  • Stefano Cascinu: No conflicts of interest to declare
  • Raphael Catane: No conflicts of interest to declare
  • Vittoria Colia: No conflicts of interest to declare
  • Nicoletta Colombo: No conflicts of interest to declare
  • Lucio Crinò: No conflicts of interest to declare
  • David Cunningham: Research funding - Roche and Amgen
  • Giannicola D’Addario: No conflicts of interest to declare
  • Louis Denis: No conflicts of interest to declare
  • Orejeta Diamanti: No conflicts of interest to declare
  • Martin Dreyling: Advisory Board: Bayer, Celgene, Gilead, Janssen, Pfizer; Consultancy/Honoraria: Celgene, Janssen, Mundipharma, Pfizer, Roche; Research funding to the institution: Celgene, Janssen, Pfizer, Mundipharma, Roche.
  • Reinhard Dummer: Research funding: Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Bristol-Myers Squibb, Roche, GlaxoSmith Klein, Bayer; Consultant or Advisory Board: Astra Zeneca, Novartis, Cephalon, Merck Sharp & Dhome, Transgene, Genta, Bayer, Roche, Bristol-Myers Squibb, GlaxoSmith Klein, Spirig.
  • Enriqueta Felip: Consultancy/Honoraria – Ely Lilly, GlaxoSmith Klein, Pfizer, Roche, Boehringer Ingelheim
  • Martin Fey: No conflicts of interest to declare
  • Matthew Fowler: No conflicts of interest to declare
  • Jorge Freitas: No conflicts of interest to declare
  • Ivan Gardini: No conflicts of interest to declare
  • Jan Geissler: No disclosure at time of going online
  • Bengt Glimelius: No conflicts of interest to declare
  • Ornella Gonzato: No conflicts of interest to declare
  • Magdalena Grce: No conflicts of interest to declare
  • Christine Haie-Meder: No conflicts of interest to declare
  • Julie Hewitt: No conflicts of interest to declare
  • Alan Horwich: His institution is inventor of abiraterone and receives royalty payments; no personal conflicts of interest
  • Svetislav Jelic: No conflicts of interest to declare
  • Anna Jewel: No conflicts of interest to declare
  • Svetlana Jezdic: No conflicts of interest to declare
  • Lorenz Jost: No conflicts of interest to declare
  • Ulrich Keilholz: Honoraria: Amgen, BMS, GSK, Glycotope, MerckSerono, Merck/MSD, Pfizer; Research support: Pfizer, MerckSerono, Innate, Sirtec.
  • Holbrook Khort: No conflicts of interest to declare
  • David Kirby: No conflicts of interest to declare
  • Gabriella Kornek: No disclosure at time of going online
  • Paris Kosmidis: No conflicts of interest to declare
  • Stella Kyriakides: No conflicts of interest to declare
  • Roberto Labianca: Research grants – Roche, Sanofi
  • Marco Ladetto: No conflicts of interest to declare
  • Michelle Lewington: No conflicts of interest to declare
  • Lisa Licitra: Advisory Board: Bristol-Myers Squibb, GlaxoSmith Klein, Ely Lilly, Merck-Serono and Amgen; Institutional funds for clinical studies and research activities in which she is involved from EISAI, Exelixis, ly Lilly, Merck-Serono, Amgen; Travel coverages to attend medical meetings Merck-Serono
  • Vanessa Marchesi: No conflicts of interest to declare
  • Anita Margulies: No conflicts of interest to declare
  • Giulio Metro: Honoraria from Anticancer Fund
  • Annemie Michiels: No conflicts of interest to declare
  • Kathy Oliver: Honoraria for Healthcare Advisory Board (“HAB” – patient advocacy board) – GlaxoSmithKline; Honoraria for Global Council of the Patient Access to Cancer Care Excellence (PACE) initiative – Eli Lilly; Honoraria as a member of E-PALCO (European Cancer Patient Leaders Council) – Novartis; Honoraria for Worldwide Oncology Advocacy Advisory Board – Bristol-Myers Squibb; Honoraria for Advisory meeting – AbbVie; Honoraria for consultancy – Eli Lilly; Speaker fee: Bayer; Consultancy work EORTC/SPAEN Training Course in “Understanding Clinical Research”; Honoraria for consultancy work SPAEN training course in patient advocacy.
    KO is a Chair and Co-Director of the International Brain Tumour Alliance (IBTA) that accepted financial support and support in kind either directly or as part of a wider grouping of patient organisations from the following companies and trusts: Accuray, Antisense Pharma, Apogenix, Archimedes, Ark Therapeutics, Astra Zeneca, Boehringer Ingelheim, Brain Tumor Network (USA), Brain Tumor Resource and Information Network (USA), Bristol-Myers Squibb (BMS), Celldex Therapeutics, Crusade, Dijon Designs (UK), Elekta, Eli Lilly, Gerry & Nancy Pencer Brain Trust (Canada), Gosling Foundation (UK), GlaxoSmithKline (GSK), Ivy Foundation (USA), Lilly, Link Pharmaceuticals, Magforce, Medac, Merck Serono, Merck, MGI Pharma, MSD Oncology, NeoPharm, Neuroendoscopy (Australia), Northwest Biotherapeutics, Novartis, Novocure, Pediatric Brain Tumor Foundation (USA), Pfizer, Photonamic, Roche, Schering-Plough (Global), Sontag Foundation (USA), Spink (UK), to-BBB, Vane Percy (UK), VBL Therapeutics, Wallerstein Foundation (USA). 
  • Alicia Okines: Honorarium and travel support - Roche
  • Ruth Payne: No conflicts of interest to declare
  • George Pentheroudakis: No conflicts of interest to declare
  • Bernhard Pestalozzi: No conflicts of interest to declare
  • Martine Piccart: Grant: Boehringer-Ingelheim, Bristol-Myers Squibb, Glaxo Smith Kline, Novartis, Pfizer; Roche, Merck; Consultant: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Roche; Advisory Board: PharmaMar
  • George Plataniotis: No conflicts of interest to declare
  • Salvatore Provenzano: No conflicts of interest to declare
  • Simonetta Rapetti: No disclosure at time of going online
  • Cristiana Sessa: No conflicts of interest to declare
  • Thomas Seufferlein: No conflicts of interest to declare
  • Silvia Stacchiotti: Research grants: Novartis, Pfizer, PharmaMar, GlaxoSmithKline, Amgen, Bayer
  • Michael Stahl: No conflicts of interest to declare
  • Roger Stupp: Honoraria or consulting fee (paid to institution): Roche, Merck KGaA/EMD-Serono, MSD/Merck & Co, Pfizer, Ipsen Pharma, Novartis.
  • Mary Tanay: No conflicts of interest to declare
  • Umberto Tassini: No conflicts of interest to declare
  • Ana Ugarte: No conflicts of interest to declare
  • Stefania Vallone: No conflicts of interest to declare
  • Eric Van Cutsem: Research funding – Amgen, MerckSerono, Pfizer, Roche, Sanofi-Aventis
  • Hilje van der Grient-Logtenberg: No conflicts of interest to declare
  • Ingo van Thiel: No conflicts of interest to declare
  • Chris Verslype: Research funding – Bayer, Sirtex, Novartis
  • Anita Waldmann: No conflicts of interest to declare
  • Markus Wartenberg: No disclosure at time of going online
  • Roger Wilson: No disclosure at time of going online
  • Hanneke Zwinkels: No conflicts of interest to declare